📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
9 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 7 fois dans les médias — pédagogie reconnue
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Médecin engagé dans la recherche académique — 3 publications référencées dans les bases scientifiques internationales, contribuant aux travaux sur perfectionism, procrastination, anxiety studies et covid-19 and mental health.
Thématiques principales
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Affiliations FR : Imaging, Brain, and Neuropsychiatry
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 mesinfos · 24/01/2026
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxOSXRNNC1HTGtrLWhteHlUU1dUTndEeVlWRm1obzFnUjFHanMycHFwWDZNSm8xbUowZlZzelpDS3p3SjN1Z24tckhnNXoxTmNnZ1RnWFk2MTdFdXpESjc4ZXNWa04zV3dIUWczVFV2TWdwb2dFTDRFZXRWR2tFcnBEY1BPNmg5U01kOUFFM2NNeHRpUDNpYnp6ZXk5YlZKcGF3MG5TU0NqOWFkTF9EWk0xTjVzSVRvblJ2Qm
📰 Le Progrès · 15/07/2025
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPU3JpUWFXbXFaM2pSQm9fc1pQY19ocDFVMXk5a1pLVEljeV9IcUtfVG1DUWVVVTVINWhPWTdiNm5ONzNKbGE5cjVBdEwyYVlDb1B5Z1dIb3FfZWd1YzcyaF84Z1dMc2d0NW1jWFJfRHZpX1JLeThoVnNWRF9tZWV3cmlPSy1laVE0U1lRLW5WTjlKd3h2bnFvTy16aFpXNFFuTUdCWDduUkZETHVfQkFsc2t3?oc=5" tar
📰 Le Bien Public · 18/03/2025
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNV19Kc0lWclZZVjd4TlBZV3N5cVg5b2NkTFBHYi0ySTNjVUVBRHdYUF9LOVRpUTVBbUY4a01BeWsxQ1lSMG96dXF4MFExem53TVhDeWw3N2Z6QWpfT3pDNFZJazQwZWxCNVhNRTJwS01SNHg1QlZnRHhBQndFSnhwamxxOTdGWlFPOWNJSElhbXR0ZWc1SGFJdkJIQUpremprMWdIeHBfckQxSlVaT3V2VmFmSFVVV0dOU2
📰 mesinfos · 20/02/2025
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNUTVCYkxZSHZRd212b0lBazY5VVVfbUlERl8taWFTQVAzbTkwQ0RGeW5uN0lvTmUxVjVSZkI4MjgycGRaLVN5R09PWFVVNlZwak9TMmd4Zm1QWDJjTC1ybUdTRjcyUTluaFowZ0JWRk5zcGlySjlGb21xb19WVGtNeVhXV0xSbmhkeEpnMUQ2X3J1aXo4a2h0NGVEUmdGVWozQ1hfN0tLbGYwSlF1Z3ZuYy1qQXRqVEk0al
📰 ici.fr · 11/09/2024
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNX2RIUEF5R1I4THVQclFnWEt4YVpzTWh4Sk9QUC1tVXFjNXFmX1MzZ1NBckF4WUhSMUJNaGRpdE5LbHNwNWlFTXBhaVRtRVlkNG8xaHZaakJVa2kxMTJoNXEzbFMxTXBwWDRqUkV3MzBJb0RPazlabmhYakx6NDdwTWVnbmc4Z3Rvb2VobnBSVkVQVlZBS244SjNrTnltUHJSbG9LMGdpWnRjUXUwMGxzcG1wdnlQZk5fNE
📰 Le Pays Roannais · 24/04/2014
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQcUhiYWRNdnk3b3Q1clZwV216QUV5UVdzV3BtSjBBMlpDY2oyRlF6ZG5RSkRVNUQweEF0MWFveGRKYWtibER1WGw5eDl3ajZXWk1PSF8zSWZjWFZ0NVBEVUZ2bGpDVVVudmtfV0RVdTFwZEQ2TERfR3RTSG5XeHFjNHUxd0JJelpYM1JqejhuZHpBejEzQXNqaHRwUmV6R3g4X1FJ?oc=5" target="_blank">Maire d
📰 lanouvellerepublique.fr · 02/06/2012
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQbGNXc29Qb2NYeDFILW83dlliWWRzNFloQWdqRGxtb1BiWU9pR1JkLVVOVXJOMzYyUnVWX296TGI2NElxamwwM2pnQm1GbWVVNGl0OEJYQTRad2VKS1ZvbmNmRS05N2RxUnZQT0wxTlp0UUl2UlpwN3duSG81a1F2akdpTlQ2bVNCcXBhc3NTaU8?oc=5" target="_blank">Période de rodage pour la Maison
Arthritis and rheumatism · 2007
AbstractObjectiveTo describe characteristics and outcomes of vasculitides associated with malignancies.MethodsThe requirement for inclusion in this retrospective, 10‐year study was development of vasculitis in patients with a progressing malignancy. Malignancies secondary to immunosuppressants used to treat vasculitis were excluded. The main characteristics of vasculitides were analyzed and compared according to the type of malignancy.ResultsSixty patients were included (male/female sex ratio 2.53, mean age 62.4 years). Mean followup duration was 45.2 months. Vasculitides were cutaneous leukocytoclastic (45%), polyarteritis nodosa (36.7%), Wegener's granulomatosis (6.7%), microscopic polyangiitis (5%), and Henoch‐Schönlein purpura (5%). Malignancies were distributed as follows: hematologic in 63.1%, myelodysplastic syndrome (MDS) in 32.3%, lymphoid in 29.2%, and solid tumor in 36.9%. Vasculitides were diagnosed concurrently with malignancy in 38% of the cases. Manifestations of vasculitides were fever (41.7%), cutaneous involvement (78.3%), arthralgias (46.7%), peripheral neuropathy (31.7%), renal involvement (23.3%; 11.7% glomerulonephritis, 11.7% microaneurysms, 6.7% renal insufficiency), and antineutrophil cytoplasmic antibody (20.4%). Vasculitis treatments were corticosteroids (78.3%) and immunosuppressant(s) (41.7%). Vasculitis was cured in 65% of patients, but 58.3% died, with 1 death secondary to vasculitis. Independent of subtype, patients with vasculitides associated with MDS more frequently had renal manifestations (P = 0.02) and steroid dependence (P = 0.04) and achieved complete remission less often (P = 0.04) than patients with vasculitides associated with other malignancies. Patients with vasculitides associated with a solid tumor more frequently had peripheral neurologic involvement (P = 0.05). Patients with vasculitides associated with lymphoid malignancy had less frequent arthralgias (P = 0.01) and renal involvement (P = 0.02).ConclusionVasculitides occurring during malignancies present distinctive features according to the vasculitis subtype and nature of the malignancy.
Blood · 2009
Abstract Evans syndrome (ES) is a rare disease characterized by the simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and/or immune neutropenia. To better describe the characteristics and outcome of ES in adults, a survey was initiated in 2005. The data from 68 patients (60% of them women) fulfilling strict inclusion criteria for ES are reported. The mean age at time of ITP and/or AIHA onset was 52 plus or minus 33 years, both cytopenias occurred simultaneously in 37 cases (54.5%). ES was considered as “primary” in 34 patients (50%) but was associated with an underlying disorder in half of the cases, including mainly systemic lupus, lymphoproliferative disorders, and common variable immunodeficiency. All patients were given corticosteroids, but 50 of them (73%) required at least one “second-line” treatment, including splenectomy(n = 19) and rituximab (n = 11). At time of analysis, after a mean follow-up of 4.8 years, only 22 patients (32%) were in remission off treatment; 16 (24%) had died. In elderly patients, the risk of cardiovascular manifestations related to AIHA seems to be higher than the ITP-related risk of severe bleeding. In conclusion, ES is a potentially life-threatening condition that may be associated with other underlying autoimmune or lymphoproliferative disorders.
The Thoracic and cardiovascular surgeon · 1996
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Frontiers in psychology · 2023 · Journal Article
Brinthaupt TM, Morin A
Laterality · 2017 · Journal Article
Morin A
European journal of internal medicine · 2011 · Journal Article
Javaud N, Certal Rda S, Stirnemann J, Morin AS, et al.
Blood · 2009 · Clinical Trial
Michel M, Chanet V, Dechartres A, Morin AS, et al.
Arthritis and rheumatism · 2007 · Journal Article
Fain O, Hamidou M, Cacoub P, Godeau B, et al.
Allergologia et immunopathologia · 1982 · Journal Article
Morin A, Ballet JJ
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2010 · Case Reports
Melboucy-Belkhir S, Flexor G, Stirnemann J, Morin AS, et al.
The Thoracic and cardiovascular surgeon · 1996 · Case Reports
Morin AM, Boyer AS, Nataf P, Gandjbakhch I
La Revue du praticien · 2007 · Case Reports
Fain O, Aras N, Morin AS, Stirnemann J
✨ Profil synthétique
IA · 19/05/2026Le Dr Alain Morin est un rhumatologue dont les recherches portent principalement sur les aspects psychologiques et les réponses au stress, notamment en lien avec la santé mentale pendant la COVID-19. Ses publications reflètent un intérêt pour les interventions basées sur la pleine conscience et la compassion. Avec un h-index de 1 et 3 publications, son travail académique est en cours de développement.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.